Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone. Erasmus, C., Aucamp, J., Smit, F., Seldon, R., Jordaan, A., Warner, D., & N'Da, D. Bioorganic chemistry, 114:105118, 2021. doi abstract bibtex A principal factor that contributes towards the failure to eradicate leishmaniasis and tuberculosis infections is the reduced efficacy of existing chemotherapies, owing to a continuous increase in multidrug-resistant strains of the causative pathogens. This accentuates the dire need to develop new and effective drugs against both plights. A series of naphthoquinone-triazole hybrids was synthesized and evaluated in vitro against Leishmania (L.) and Mycobacterium tuberculosis (Mtb) strains. Their cytotoxicities were also evaluated, using the human embryonic kidney cell line (HEK-293). The hybrids were found to be non-toxic towards human cells and had demonstrated micromolar cellular antileishmanial and antimycobacterial potencies. Hybrid 13, i.e. 2-\[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy\naphthalene-1,4-dione was the most active of all. It was found with MIC90 0.5 µM potency against Mtb in a protein free medium, and with half-maxima inhibitory concentrations (IC50) of 0.81 µM and 1.48 µM against the infective promastigote parasites of L. donavani and L. major, respectively, with good selectivity towards these pathogens (SI 22 - 65). Comparatively, the clinical naphthoquinone, atovaquone, although less cytotoxic, was found to be two-fold less antimycobacterial potent, and six- to twelve-fold less active against leishmania. Hybrid 13 may therefore stand as a potential anti-infective hit for further development in the search for new antitubercular and antileishmanial drugs. Elucidation of its exact mechanism of action and molecular targets will constitute future endeavour.
@article{Erasmus2021,
abstract = {A principal factor that contributes towards the failure to eradicate leishmaniasis and tuberculosis infections is the reduced efficacy of existing chemotherapies, owing to a continuous increase in multidrug-resistant strains of the causative pathogens. This accentuates the dire need to develop new and effective drugs against both plights. A series of naphthoquinone-triazole hybrids was synthesized and evaluated in vitro against Leishmania (L.) and Mycobacterium tuberculosis (Mtb) strains. Their cytotoxicities were also evaluated, using the human embryonic kidney cell line (HEK-293). The hybrids were found to be non-toxic towards human cells and had demonstrated micromolar cellular antileishmanial and antimycobacterial potencies. Hybrid 13, i.e. 2-{\{}[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy{\}}naphthalene-1,4-dione was the most active of all. It was found with MIC90 0.5 µM potency against Mtb in a protein free medium, and with half-maxima inhibitory concentrations (IC50) of 0.81 µM and 1.48 µM against the infective promastigote parasites of L. donavani and L. major, respectively, with good selectivity towards these pathogens (SI 22 - 65). Comparatively, the clinical naphthoquinone, atovaquone, although less cytotoxic, was found to be two-fold less antimycobacterial potent, and six- to twelve-fold less active against leishmania. Hybrid 13 may therefore stand as a potential anti-infective hit for further development in the search for new antitubercular and antileishmanial drugs. Elucidation of its exact mechanism of action and molecular targets will constitute future endeavour.},
author = {Erasmus, C. and Aucamp, J. and Smit, F.J. and Seldon, R. and Jordaan, A. and Warner, D.F. and N'Da, D.D.},
doi = {10.1016/j.bioorg.2021.105118},
journal = {Bioorganic chemistry},
pages = {105118},
title = {{Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone}},
volume = {114},
year = {2021}
}
Downloads: 0
{"_id":"PY7RFQqrmhArnNFSt","bibbaseid":"erasmus-aucamp-smit-seldon-jordaan-warner-nda-synthesisandcomparisonofinvitrodualantiinfectiveactivitiesofnovelnaphthoquinonehybridsandatovaquone-2021","author_short":["Erasmus, C.","Aucamp, J.","Smit, F.","Seldon, R.","Jordaan, A.","Warner, D.","N'Da, D."],"bibdata":{"bibtype":"article","type":"article","abstract":"A principal factor that contributes towards the failure to eradicate leishmaniasis and tuberculosis infections is the reduced efficacy of existing chemotherapies, owing to a continuous increase in multidrug-resistant strains of the causative pathogens. This accentuates the dire need to develop new and effective drugs against both plights. A series of naphthoquinone-triazole hybrids was synthesized and evaluated in vitro against Leishmania (L.) and Mycobacterium tuberculosis (Mtb) strains. Their cytotoxicities were also evaluated, using the human embryonic kidney cell line (HEK-293). The hybrids were found to be non-toxic towards human cells and had demonstrated micromolar cellular antileishmanial and antimycobacterial potencies. Hybrid 13, i.e. 2-\\[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy\\naphthalene-1,4-dione was the most active of all. It was found with MIC90 0.5 µM potency against Mtb in a protein free medium, and with half-maxima inhibitory concentrations (IC50) of 0.81 µM and 1.48 µM against the infective promastigote parasites of L. donavani and L. major, respectively, with good selectivity towards these pathogens (SI 22 - 65). Comparatively, the clinical naphthoquinone, atovaquone, although less cytotoxic, was found to be two-fold less antimycobacterial potent, and six- to twelve-fold less active against leishmania. Hybrid 13 may therefore stand as a potential anti-infective hit for further development in the search for new antitubercular and antileishmanial drugs. Elucidation of its exact mechanism of action and molecular targets will constitute future endeavour.","author":[{"propositions":[],"lastnames":["Erasmus"],"firstnames":["C."],"suffixes":[]},{"propositions":[],"lastnames":["Aucamp"],"firstnames":["J."],"suffixes":[]},{"propositions":[],"lastnames":["Smit"],"firstnames":["F.J."],"suffixes":[]},{"propositions":[],"lastnames":["Seldon"],"firstnames":["R."],"suffixes":[]},{"propositions":[],"lastnames":["Jordaan"],"firstnames":["A."],"suffixes":[]},{"propositions":[],"lastnames":["Warner"],"firstnames":["D.F."],"suffixes":[]},{"propositions":[],"lastnames":["N'Da"],"firstnames":["D.D."],"suffixes":[]}],"doi":"10.1016/j.bioorg.2021.105118","journal":"Bioorganic chemistry","pages":"105118","title":"Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone","volume":"114","year":"2021","bibtex":"@article{Erasmus2021,\nabstract = {A principal factor that contributes towards the failure to eradicate leishmaniasis and tuberculosis infections is the reduced efficacy of existing chemotherapies, owing to a continuous increase in multidrug-resistant strains of the causative pathogens. This accentuates the dire need to develop new and effective drugs against both plights. A series of naphthoquinone-triazole hybrids was synthesized and evaluated in vitro against Leishmania (L.) and Mycobacterium tuberculosis (Mtb) strains. Their cytotoxicities were also evaluated, using the human embryonic kidney cell line (HEK-293). The hybrids were found to be non-toxic towards human cells and had demonstrated micromolar cellular antileishmanial and antimycobacterial potencies. Hybrid 13, i.e. 2-{\\{}[1-(4-methylbenzyl)-1H-1,2,3-triazol-4-yl]methoxy{\\}}naphthalene-1,4-dione was the most active of all. It was found with MIC90 0.5 µM potency against Mtb in a protein free medium, and with half-maxima inhibitory concentrations (IC50) of 0.81 µM and 1.48 µM against the infective promastigote parasites of L. donavani and L. major, respectively, with good selectivity towards these pathogens (SI 22 - 65). Comparatively, the clinical naphthoquinone, atovaquone, although less cytotoxic, was found to be two-fold less antimycobacterial potent, and six- to twelve-fold less active against leishmania. Hybrid 13 may therefore stand as a potential anti-infective hit for further development in the search for new antitubercular and antileishmanial drugs. Elucidation of its exact mechanism of action and molecular targets will constitute future endeavour.},\nauthor = {Erasmus, C. and Aucamp, J. and Smit, F.J. and Seldon, R. and Jordaan, A. and Warner, D.F. and N'Da, D.D.},\ndoi = {10.1016/j.bioorg.2021.105118},\njournal = {Bioorganic chemistry},\npages = {105118},\ntitle = {{Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone}},\nvolume = {114},\nyear = {2021}\n}\n","author_short":["Erasmus, C.","Aucamp, J.","Smit, F.","Seldon, R.","Jordaan, A.","Warner, D.","N'Da, D."],"key":"Erasmus2021","id":"Erasmus2021","bibbaseid":"erasmus-aucamp-smit-seldon-jordaan-warner-nda-synthesisandcomparisonofinvitrodualantiinfectiveactivitiesofnovelnaphthoquinonehybridsandatovaquone-2021","role":"author","urls":{},"metadata":{"authorlinks":{}}},"bibtype":"article","biburl":"https://drive.google.com/uc?export=download&id=1-9gwO2GBrWfUK-fFo05cgfzXdRK_w9xL","dataSources":["wrEvssexmuYudwQw9","9bX4N36CTXtCXNFMd","6GMFi5DCojy3jHY44"],"keywords":[],"search_terms":["synthesis","comparison","vitro","dual","anti","infective","activities","novel","naphthoquinone","hybrids","atovaquone","erasmus","aucamp","smit","seldon","jordaan","warner","n'da"],"title":"Synthesis and comparison of in vitro dual anti-infective activities of novel naphthoquinone hybrids and atovaquone","year":2021}